Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis)
injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and
eliminate the need for panretinal photocoagulation in patients with ischemic central retinal
vein occlusion.